amiodarone has been researched along with Torsade de Pointes in 103 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Torsade de pointes is rarely associated with chronic amiodarone treatment, despite the effect of amiodarone on QT interval prolongation." | 8.82 | Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. ( Antonelli, D; Atar, S; Freedberg, NA; Rosenfeld, T, 2005) |
| "To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias or the development of new arrhythmias, such as torsade de pointes, in patients with cardiac disease." | 8.79 | Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. ( Hohnloser, SH; Klingenheben, T; Singh, BN, 1994) |
| " Approximately 6 days after starting intravenous administration of amiodarone (600 mg/day) for maintaining sinus rhythm after cardioversion of AF, electrocardiograms revealed a prolonged QT interval associated with torsade de pointes (TdP)." | 8.02 | Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy. ( Enomoto, D; Hyodo, T; Ikeda, S; Okura, T; Sakaue, T; Takahashi, K; Takemoto, M; Uemura, S; Utsunomiya, Y; Yamashita, M, 2021) |
| "One of the drugs that are widely used in the treatment of atrial fibrillation is amiodarone." | 7.91 | TORSADES DE POINTES IN ELDERLY PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION TREATED BY SHORT-TERM PARENTERAL AMIODARONE THERAPY. ( Cerovec, D; Ciglenečki, N; Lakušić, N; Slivnjak, V, 2019) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 7.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| " During amiodarone infusion a torsade de pointes occurred, which was immediately converted to sinus rhythm by synchronized cardioversion." | 7.75 | "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. ( Benazzi, B; Bernardi, M; Berzigotti, A; Bracci, E; Di Micoli, A; Trevisani, F; Zambruni, A; Zappoli, P; Zoli, M, 2009) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Amiodarone is one of the most efficient and safe antiarrhythmic drugs in the treatment of atrial fibrillation (AF)." | 7.73 | "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. ( Bitzen, A; Lewalter, T; Lüderitz, B; Schrickel, JW; Schwab, JO; Yang, A, 2006) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 7.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| "Amiodarone-associated torsade de pointes (Tdp) has been reported increasingly in China in recent years." | 7.73 | Clinical study of amiodarone-associated torsade de pointes in Chinese people. ( Geng, DF; Jin, DM; Luo, YJ; Wang, JF; Wu, W, 2006) |
| "Five patients with amiodarone-induced QT prolongation and torsade de pointes are described." | 7.72 | [Amiodarone-induced torsade de pointes--five case reports]. ( Kukla, P; Słowiak-Lewińska, T, 2004) |
| "The study included 70 patients who were treated with long-term oral amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or flutter (13 of 70, 19%)." | 7.71 | Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. ( Chatterjee, K; Cheng, J; Glatter, K; Kayser, S; Modin, G; Scheinman, MM; Yang, Y, 2001) |
| "Amiodarone is an effective antiarrhythmic drug rarely associated with torsade de pointes arrhythmias (TdP)." | 7.71 | Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. ( de Groot, SH; Leunissen, JD; Molenschot, MM; Schoenmakers, M; van Der Hulst, FF; van Opstal, JM; Verduyn, SC; Vos, MA; Wellens, HJ, 2001) |
| "Patients with a history of class Ia drug-induced torsade de pointes have been treated with chronic amiodarone without recurrence of torsade de pointes despite comparable prolongation of the QT interval." | 7.68 | Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. ( Duff, HJ; Gillis, AM; Hii, JT; Mitchell, LB; Solylo, MA; Wyse, DG, 1992) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 7.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "Torsade de pointes, a polymorphous ventricular tachycardia, is a well-known but rarely occurring cardiac adverse drug reaction under amiodarone, a class-III antiarrhythmic agent." | 7.68 | [Torsade de pointes during anti-arrhythmia treatment with amiodarone]. ( Haefeli, WE; Lüscher, TF; Schlienger, RG, 1993) |
| "The incidence of torsade de pointes associated with amiodarone, however, is reported to be much lower." | 6.40 | Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade. ( Green, MS; Morton, BC; Skanes, AC; Tang, AS, 1997) |
| "Thereafter nonsustained torsade de pointes (TdP) tachycardia occurred." | 5.42 | Torsade de pointes tachycardia in a patient on dronedarone therapy. ( Bronder, E; Garbe, E; Haverkamp, W; Huemer, M; Klimpel, A; Sarganas, G, 2015) |
| "Amiodarone pre-treatment led to a prolongation of APD(90) (+19 ms) as compared with sham-controlled hearts but showed only a marginal effect on APD(90) in failing hearts." | 5.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| "A 70-year-old woman with dilated cardiomyopathy and ventricular tachyarrhythmia was initially treated in 1990 with intravenous amiodarone (240 mg)." | 5.31 | Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy. ( Kuga, K; Yamada, S; Yamaguchi, I, 2001) |
| "The patient had severe dilated cardiomyopathy, and even though he was treated with low oral doses of amiodarone, without dosage increments and electrolyte imbalance, he developed torsade de pointes at nights, after T-wave modification and increases of the corrected QT interval (QTc, 20%), QT dispersion (QTd, 175%) and QTcd (116%)." | 5.31 | Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy. ( Bevilacqua, M; Drago, F; Ragonese, P; Silvetti, MS, 2001) |
| "D-sotalol and almokalant evoked torsade de pointes (TdP) and other arrhythmics, frequently." | 5.31 | Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. ( Farkas, A; Leprán, I; Papp, JG, 2002) |
| "Almokalant-induced TdP was characterized by an increased repolarization duration, deltaAPD, and EADs." | 5.30 | Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. ( Leunissen, HD; van Opstal, JM; Verduyn, SC; Vos, MA; Wellens, HJ, 1999) |
| " Sotalol, dofetilide, and ibutilide may induce torsade de pointes in 2-8% of patients, whereas amiodarone induces torsade de pointes in less than 1%." | 4.84 | Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. ( Kluger, J; Shah, SA; White, CM, 2007) |
| "To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias or the development of new arrhythmias, such as torsade de pointes, in patients with cardiac disease." | 4.79 | Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. ( Hohnloser, SH; Klingenheben, T; Singh, BN, 1994) |
| " Approximately 6 days after starting intravenous administration of amiodarone (600 mg/day) for maintaining sinus rhythm after cardioversion of AF, electrocardiograms revealed a prolonged QT interval associated with torsade de pointes (TdP)." | 4.02 | Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy. ( Enomoto, D; Hyodo, T; Ikeda, S; Okura, T; Sakaue, T; Takahashi, K; Takemoto, M; Uemura, S; Utsunomiya, Y; Yamashita, M, 2021) |
| "One of the drugs that are widely used in the treatment of atrial fibrillation is amiodarone." | 3.91 | TORSADES DE POINTES IN ELDERLY PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION TREATED BY SHORT-TERM PARENTERAL AMIODARONE THERAPY. ( Cerovec, D; Ciglenečki, N; Lakušić, N; Slivnjak, V, 2019) |
| " We present the case of 52-year-old male who was treated with clarithromycin due to bilateral atypical pneumonia." | 3.80 | Cardiac arrest and electrical storm due to recurrent torsades de pointes caused by concomitant clarithromycin, cotrimoxazole and amiodarone treatment. ( Bienias, P; Ciurzyński, M; Paczyńska, M; Pruszczyk, P, 2014) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed after administration of a low dose and short term use of oral amiodarone, in the absence of predisposing factors." | 3.80 | Intermittent QT prolongation induced by short-term oral amiodarone therapy. ( Amasyalı, B; Astarcioglu, MA; Durmuş, HI; Sen, T, 2014) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 3.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "To characterize the frequency and type of cardiac events, including torsade de pointes, associated with dronedarone and its structural analog, amiodarone, outside of the clinical trial setting." | 3.78 | Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. ( Hiatt, WR; Kao, DP; Krantz, MJ, 2012) |
| " After amiodarone administration, the electrocardiogram showed marked QT prolongation associated with ventricular arrhythmias, including an episode of torsade de pointes requiring immediate electrical cardioversion." | 3.78 | A dangerous fruit juice. ( Agosti, S; Barsotti, A; Bertero, G; Brunelli, C; Casalino, L; Morelloni, S, 2012) |
| " In the first case, the drugs venlafaxine, amiodarone and domperidone may have contributed to QT interval prolongation in a patient with hypokalemia and hypomagnesaemia." | 3.76 | Multifactorial QT interval prolongation. ( Baranchuk, A; Digby, G; Machaalany, J; Malik, P; Methot, M; Redfearn, D; Simpson, CS, 2010) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| " During amiodarone infusion a torsade de pointes occurred, which was immediately converted to sinus rhythm by synchronized cardioversion." | 3.75 | "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. ( Benazzi, B; Bernardi, M; Berzigotti, A; Bracci, E; Di Micoli, A; Trevisani, F; Zambruni, A; Zappoli, P; Zoli, M, 2009) |
| "This report documents the occurrence of torsades de pointes (TdP) caused by marked QT interval prolongation in the case of a 71-year-old woman receiving both metronidazole and amiodarone for the treatment of pseudomembranous colitis and paroxysmal atrial fibrillation." | 3.73 | QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. ( Efraimidis, M; Kardaras, F; Kounas, SP; Letsas, KP; Sideris, A, 2005) |
| "Amiodarone is one of the most efficient and safe antiarrhythmic drugs in the treatment of atrial fibrillation (AF)." | 3.73 | "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. ( Bitzen, A; Lewalter, T; Lüderitz, B; Schrickel, JW; Schwab, JO; Yang, A, 2006) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 3.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| " The incidence of clinical torsade de pointes (TdP) associated with amiodarone has been reported to be low and the present study compared the proarrhythmic potential of amiodarone with that of a selective IKr channel blocker, sematilide, using a canine chronic atrioventrucular block model." | 3.71 | Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. ( Hashimoto, K; Ishida, Y; Kugiyama, K; Satoh, Y; Sugiyama, A; Yoneyama, M; Yoshida, H, 2002) |
| "The study included 70 patients who were treated with long-term oral amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or flutter (13 of 70, 19%)." | 3.71 | Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. ( Chatterjee, K; Cheng, J; Glatter, K; Kayser, S; Modin, G; Scheinman, MM; Yang, Y, 2001) |
| "Amiodarone is an effective antiarrhythmic drug rarely associated with torsade de pointes arrhythmias (TdP)." | 3.71 | Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. ( de Groot, SH; Leunissen, JD; Molenschot, MM; Schoenmakers, M; van Der Hulst, FF; van Opstal, JM; Verduyn, SC; Vos, MA; Wellens, HJ, 2001) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "Torsade de pointes, a polymorphous ventricular tachycardia, is a well-known but rarely occurring cardiac adverse drug reaction under amiodarone, a class-III antiarrhythmic agent." | 3.68 | [Torsade de pointes during anti-arrhythmia treatment with amiodarone]. ( Haefeli, WE; Lüscher, TF; Schlienger, RG, 1993) |
| "Torsade de pointes may occur as a complication of amiodarone therapy." | 3.68 | Sudden cardiac death while taking amiodarone therapy: the role of abnormal repolarization. ( Lopes, A; Morgan, JM; Rowland, E, 1991) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 3.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "Patients with a history of class Ia drug-induced torsade de pointes have been treated with chronic amiodarone without recurrence of torsade de pointes despite comparable prolongation of the QT interval." | 3.68 | Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. ( Duff, HJ; Gillis, AM; Hii, JT; Mitchell, LB; Solylo, MA; Wyse, DG, 1992) |
| "An intravenous bolus injection and subsequent continuous infusion of NIF at a relatively low dosage were effective in treating severe ventricular tachyarrhythmias complicating ACS, reducing the potential risk of proarrhythmia." | 2.74 | Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. ( Abe, A; Ikeda, T; Ishiguro, H; Mera, H; Miwa, Y; Miyakoshi, M; Shimizu, H; Tsukada, T; Yoshino, H; Yusu, S, 2009) |
| "The short QT syndrome has been recently recognised as a genetic ion channel dysfunction." | 2.43 | Short QT syndrome: a case report and review of literature. ( Cao, Q; Lu, LX; Yu, K; Zhang, X; Zhou, W; Zhu, C, 2006) |
| "The prevalence of arrhythmia in the population is increasing as more people survive for longer with cardiovascular disease." | 2.42 | A benefit-risk assessment of class III antiarrhythmic agents. ( Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Pehrson, S; Torp-Petersen, C, 2004) |
| "Drugs can cause cardiac arrhythmias in a number of clinical situations, and many of the implicated agents are used to treat non-cardiac conditions." | 2.40 | Drug-induced cardiac arrhythmias: incidence, prevention and management. ( Doig, JC, 1997) |
| "Torsades de pointes is the classic form of proarrhythmia observed during therapy with any drug that prolongs repolarization, for example, the class III agents." | 2.40 | Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. ( Hohnloser, SH, 1997) |
| " Investigators have hoped that these drugs would be as effective as sotalol and amiodarone but have fewer adverse effects." | 2.40 | The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. ( MacNeil, DJ, 1997) |
| "Proarrhythmia is defined as the developmental of a new arrhythmia, or the worsening of a preexisting arrhythmia, following the institution of anti-arrhythmic therapy." | 2.39 | What have clinical trials taught us about proarrhythmia? ( Green, MS; Skanes, AC, 1996) |
| "For some arrhythmias, such as atrial fibrillation, it seems likely that drug therapy will remain an important part of treatment." | 2.39 | Is there a need for new antiarrhythmic drugs? ( Roden, DM, 1996) |
| "Amiodarone treatment was stopped, and magnesium sulfate was infused." | 1.56 | Torsade de pointes in initiating hemodialysis: a case report. ( Bae, EH; Choi, HS; Kim, CS; Kim, SW; Ma, SK; Yang, JA, 2020) |
| "Anti-atrial fibrillatory and proarrhythmic potentials of amiodarone were simultaneously analyzed by using the halothane-anesthetized beagle dogs (n = 4) in order to begin to prepare standard protocol for clarifying both efficacy and adverse effects of anti-atrial fibrillatory drugs." | 1.46 | Anti-atrial Fibrillatory Versus Proarrhythmic Potentials of Amiodarone: A New Protocol for Safety Evaluation In Vivo. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "Amiodarone was the most prescribed drug with a definite risk of TdP." | 1.43 | Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. ( Ardoino, I; Biganzoli, EM; Corrao, S; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Rossio, R; Tettamanti, M, 2016) |
| "Thereafter nonsustained torsade de pointes (TdP) tachycardia occurred." | 1.42 | Torsade de pointes tachycardia in a patient on dronedarone therapy. ( Bronder, E; Garbe, E; Haverkamp, W; Huemer, M; Klimpel, A; Sarganas, G, 2015) |
| "Amiodarone pre-treatment led to a prolongation of APD(90) (+19 ms) as compared with sham-controlled hearts but showed only a marginal effect on APD(90) in failing hearts." | 1.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| "To investigate spontaneous reports of TdP present in the public version of the FDA Adverse Event Reporting System (AERS) in the light of what is already known on their TdP-liability." | 1.35 | Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). ( De Ponti, F; Moretti, U; Poluzzi, E; Raschi, E, 2009) |
| " The QT interval was prolonged after the administration of bepridil and amiodarone, and torsades de pointes arrhythmia was induced in 3 out of 4 dogs after the bepridil administration, which was not observed during the chronic administration of amiodarone." | 1.35 | Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone. ( Nakamura, Y; Sugiyama, A; Takahara, A, 2008) |
| "In amiodarone-treated, hypokalemic hearts, no EAD or TdP occurred." | 1.32 | Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. ( Breithardt, G; Eckardt, L; Haverkamp, W; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Wasmer, K, 2004) |
| "The most prevalent inclusion bradyarrhythmia was > or =second-degree AV block (82%)." | 1.32 | Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia. ( Almendral, J; Arenal, A; Díaz-Castro, O; Martínez-Selles, M; Puchol, A; Torrecilla, EG, 2004) |
| "A 70-year-old woman with dilated cardiomyopathy and ventricular tachyarrhythmia was initially treated in 1990 with intravenous amiodarone (240 mg)." | 1.31 | Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy. ( Kuga, K; Yamada, S; Yamaguchi, I, 2001) |
| "The patient had severe dilated cardiomyopathy, and even though he was treated with low oral doses of amiodarone, without dosage increments and electrolyte imbalance, he developed torsade de pointes at nights, after T-wave modification and increases of the corrected QT interval (QTc, 20%), QT dispersion (QTd, 175%) and QTcd (116%)." | 1.31 | Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy. ( Bevilacqua, M; Drago, F; Ragonese, P; Silvetti, MS, 2001) |
| "D-sotalol and almokalant evoked torsade de pointes (TdP) and other arrhythmics, frequently." | 1.31 | Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. ( Farkas, A; Leprán, I; Papp, JG, 2002) |
| "Almokalant-induced TdP was characterized by an increased repolarization duration, deltaAPD, and EADs." | 1.30 | Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. ( Leunissen, HD; van Opstal, JM; Verduyn, SC; Vos, MA; Wellens, HJ, 1999) |
| "Amiodarone-induced torsades de pointes is very rare." | 1.29 | ['Cardiac ballet' with and without amiodarone]. ( Balestra, B; Hess, T, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (30.10) | 18.2507 |
| 2000's | 39 (37.86) | 29.6817 |
| 2010's | 27 (26.21) | 24.3611 |
| 2020's | 6 (5.83) | 2.80 |
| Authors | Studies |
|---|---|
| Mirams, GR | 1 |
| Cui, Y | 1 |
| Sher, A | 1 |
| Fink, M | 2 |
| Cooper, J | 1 |
| Heath, BM | 1 |
| McMahon, NC | 1 |
| Gavaghan, DJ | 1 |
| Noble, D | 2 |
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 1 |
| Savona, SJ | 1 |
| Daoud, EG | 1 |
| Arias, MA | 1 |
| Pachón, M | 1 |
| Loughlin, G | 1 |
| Yang, JA | 1 |
| Choi, HS | 1 |
| Bae, EH | 1 |
| Ma, SK | 1 |
| Kim, SW | 1 |
| Kim, CS | 1 |
| Lakušić, N | 1 |
| Slivnjak, V | 1 |
| Ciglenečki, N | 1 |
| Cerovec, D | 1 |
| Yonai, R | 1 |
| Kawabata, M | 1 |
| Maeda, S | 1 |
| Kawashima, T | 1 |
| Tsuda, Y | 1 |
| Nakasone, T | 1 |
| Nakane, H | 1 |
| Hirao, K | 1 |
| Takahashi, K | 1 |
| Yamashita, M | 1 |
| Sakaue, T | 1 |
| Enomoto, D | 1 |
| Uemura, S | 1 |
| Okura, T | 1 |
| Ikeda, S | 1 |
| Takemoto, M | 1 |
| Utsunomiya, Y | 1 |
| Hyodo, T | 1 |
| Lee, S | 1 |
| Kittleson, MD | 1 |
| Wei, A | 1 |
| Peng, J | 1 |
| Gu, Z | 1 |
| Li, J | 1 |
| Tarapués, M | 1 |
| Cereza, G | 1 |
| Arellano, AL | 1 |
| Montané, E | 1 |
| Figueras, A | 1 |
| Jhuo, SJ | 1 |
| Tang, WH | 1 |
| Lai, WT | 1 |
| Lee, KT | 1 |
| Astarcioglu, MA | 1 |
| Durmuş, HI | 1 |
| Sen, T | 1 |
| Amasyalı, B | 1 |
| Bienias, P | 1 |
| Ciurzyński, M | 1 |
| Paczyńska, M | 1 |
| Pruszczyk, P | 1 |
| Stiefelhagen, P | 1 |
| Huemer, M | 1 |
| Sarganas, G | 1 |
| Bronder, E | 1 |
| Klimpel, A | 1 |
| Garbe, E | 1 |
| Haverkamp, W | 2 |
| Franchi, C | 1 |
| Ardoino, I | 1 |
| Rossio, R | 1 |
| Nobili, A | 1 |
| Biganzoli, EM | 1 |
| Marengoni, A | 1 |
| Marcucci, M | 1 |
| Pasina, L | 1 |
| Tettamanti, M | 1 |
| Corrao, S | 1 |
| Mannucci, PM | 1 |
| Matsukura, S | 1 |
| Nakamura, Y | 2 |
| Cao, X | 1 |
| Wada, T | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Sugiyama, A | 3 |
| Beyer, A | 1 |
| Ganti, B | 1 |
| Majkrzak, A | 1 |
| Theyyunni, N | 1 |
| Takahara, A | 1 |
| Poluzzi, E | 1 |
| Raschi, E | 1 |
| Moretti, U | 1 |
| De Ponti, F | 1 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Yusu, S | 1 |
| Ikeda, T | 1 |
| Mera, H | 1 |
| Miyakoshi, M | 1 |
| Miwa, Y | 1 |
| Abe, A | 1 |
| Tsukada, T | 1 |
| Ishiguro, H | 1 |
| Shimizu, H | 1 |
| Yoshino, H | 1 |
| Digby, G | 1 |
| Machaalany, J | 1 |
| Malik, P | 1 |
| Methot, M | 2 |
| Simpson, CS | 2 |
| Redfearn, D | 1 |
| Baranchuk, A | 2 |
| Zeineh, NS | 1 |
| Agosti, S | 1 |
| Casalino, L | 1 |
| Bertero, G | 1 |
| Barsotti, A | 1 |
| Brunelli, C | 1 |
| Morelloni, S | 1 |
| Burrows, K | 1 |
| Fox, J | 1 |
| Biblo, LA | 1 |
| Roth, JA | 1 |
| Werner, CR | 1 |
| Riessen, R | 1 |
| Gregor, M | 1 |
| Bitzer, M | 1 |
| Fayssoil, A | 1 |
| Issi, J | 1 |
| Guerbaa, M | 1 |
| Raynaud, JC | 1 |
| Heroguelle, V | 1 |
| Frommeyer, G | 3 |
| Milberg, P | 4 |
| Witte, P | 1 |
| Stypmann, J | 2 |
| Koopmann, M | 1 |
| Lücke, M | 1 |
| Osada, N | 4 |
| Breithardt, G | 4 |
| Fehr, M | 1 |
| Eckardt, L | 4 |
| Digby, GC | 1 |
| Pérez Riera, AR | 1 |
| Barbosa Barros, R | 1 |
| Redfearn, DP | 1 |
| Femenía, F | 1 |
| Uphaus, T | 1 |
| Kaiser, D | 1 |
| Pott, C | 1 |
| Ruhe, M | 1 |
| Matsuda, T | 1 |
| Baba, A | 1 |
| Klocke, R | 1 |
| Quang, TH | 1 |
| Nikol, S | 1 |
| Müller, FU | 1 |
| Morris, D | 1 |
| Cameron, N | 1 |
| Kawaguchi, T | 1 |
| Takasugi, N | 1 |
| Kubota, T | 1 |
| Takasugi, M | 1 |
| Kanamori, H | 1 |
| Ushikoshi, H | 1 |
| Hattori, A | 1 |
| Aoyama, T | 1 |
| Kawasaki, M | 1 |
| Nishigaki, K | 1 |
| Takemura, G | 1 |
| Minatoguchi, S | 1 |
| Verrier, RL | 1 |
| Jamshidi, Y | 1 |
| Nolte, IM | 1 |
| Dalageorgou, C | 1 |
| Zheng, D | 1 |
| Johnson, T | 1 |
| Bastiaenen, R | 1 |
| Ruddy, S | 1 |
| Talbott, D | 1 |
| Norris, KJ | 1 |
| Snieder, H | 1 |
| George, AL | 1 |
| Marshall, V | 1 |
| Shakir, S | 1 |
| Kannankeril, PJ | 1 |
| Munroe, PB | 1 |
| Camm, AJ | 1 |
| Jeffery, S | 1 |
| Roden, DM | 2 |
| Behr, ER | 1 |
| Kao, DP | 1 |
| Hiatt, WR | 1 |
| Krantz, MJ | 1 |
| Yoshida, H | 1 |
| Satoh, Y | 1 |
| Ishida, Y | 1 |
| Yoneyama, M | 1 |
| Kugiyama, K | 1 |
| Hashimoto, K | 1 |
| Makai, A | 1 |
| Rudas, L | 1 |
| Liszkai, G | 1 |
| Fazekas, T | 1 |
| Wolbrette, DL | 1 |
| Atar, S | 2 |
| Freedberg, NA | 2 |
| Antonelli, D | 2 |
| Rosenfeld, T | 2 |
| Schrickel, J | 1 |
| Bielik, H | 1 |
| Yang, A | 2 |
| Schwab, JO | 2 |
| Shlevkov, N | 1 |
| Schimpf, R | 1 |
| Lüderitz, B | 2 |
| Lewalter, T | 2 |
| Díaz-Castro, O | 1 |
| Puchol, A | 1 |
| Almendral, J | 1 |
| Torrecilla, EG | 1 |
| Arenal, A | 1 |
| Martínez-Selles, M | 1 |
| Kukla, P | 1 |
| Słowiak-Lewińska, T | 1 |
| Lee Hwang, D | 1 |
| Barriales Alvarez, V | 1 |
| Lasa Larraya, G | 1 |
| Rondán Murillo, J | 1 |
| Ramtin, S | 1 |
| Mönnig, G | 1 |
| Wasmer, K | 1 |
| Elming, H | 1 |
| Brendorp, B | 1 |
| Pehrson, S | 1 |
| Pedersen, OD | 1 |
| Køber, L | 1 |
| Torp-Petersen, C | 1 |
| Viskin, S | 1 |
| Rosovski, U | 1 |
| Kounas, SP | 2 |
| Letsas, KP | 2 |
| Sideris, A | 2 |
| Efraimidis, M | 1 |
| Kardaras, F | 2 |
| Zimetbaum, PJ | 1 |
| Josephson, ME | 1 |
| Filippatos, GS | 1 |
| Efremidis, M | 1 |
| Somberg, J | 1 |
| Molnar, J | 1 |
| Schrickel, JW | 1 |
| Bitzen, A | 1 |
| Kijtawornrat, A | 1 |
| Nishijima, Y | 1 |
| Roche, BM | 1 |
| Keene, BW | 1 |
| Hamlin, RL | 1 |
| Bridgman, PG | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Wang, JF | 1 |
| Luo, YJ | 1 |
| Wu, W | 1 |
| Lu, LX | 1 |
| Zhou, W | 1 |
| Zhang, X | 1 |
| Cao, Q | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Lim, HE | 1 |
| Pak, HN | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kim, YH | 1 |
| Lehtonen, A | 1 |
| Fodstad, H | 1 |
| Laitinen-Forsblom, P | 1 |
| Toivonen, L | 1 |
| Kontula, K | 1 |
| Swan, H | 1 |
| Mironchik, EV | 1 |
| Dolgosheĭ, TS | 1 |
| Liskovich, TG | 1 |
| Madeshkina, GA | 1 |
| Kokhkovski, AB | 1 |
| Tyshchenko, AD | 1 |
| Foley, P | 1 |
| Kalra, P | 1 |
| Andrews, N | 1 |
| Shah, SA | 1 |
| Kluger, J | 2 |
| White, CM | 1 |
| Wegener, FT | 1 |
| Ehrlich, JR | 1 |
| Hohnloser, SH | 4 |
| Turner, S | 1 |
| Mathews, L | 1 |
| Pandharipande, P | 1 |
| Thompson, R | 1 |
| Di Micoli, A | 1 |
| Zambruni, A | 1 |
| Bracci, E | 1 |
| Benazzi, B | 1 |
| Zappoli, P | 1 |
| Berzigotti, A | 1 |
| Zoli, M | 1 |
| Bernardi, M | 1 |
| Trevisani, F | 1 |
| Middlekauff, HR | 1 |
| Stevenson, WG | 1 |
| Saxon, LA | 1 |
| Stevenson, LW | 1 |
| Schlienger, RG | 1 |
| Haefeli, WE | 1 |
| Lüscher, TF | 1 |
| van de Loo, A | 2 |
| Klingenheben, T | 2 |
| Cheng, TO | 1 |
| Singh, BN | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Hohnloser, S | 1 |
| Just, H | 1 |
| Makkar, RR | 1 |
| Fromm, BS | 1 |
| Steinman, RT | 1 |
| Meissner, MD | 1 |
| Lehmann, MH | 1 |
| Balestra, B | 1 |
| Hess, T | 1 |
| Skanes, AC | 2 |
| Green, MS | 2 |
| Genth, S | 1 |
| Darius, H | 1 |
| Zotz, R | 1 |
| Treese, N | 1 |
| Himmrich, E | 1 |
| Meyer, J | 1 |
| Faggiano, P | 2 |
| Gardini, A | 2 |
| D'Aloia, A | 2 |
| Benedini, G | 1 |
| Giordano, A | 1 |
| Ostermaier, R | 1 |
| von Essen, R | 1 |
| Morton, BC | 1 |
| Tang, AS | 1 |
| Tran, HT | 1 |
| Chow, MS | 1 |
| Doig, JC | 1 |
| MacNeil, DJ | 1 |
| Verduyn, SC | 2 |
| Vos, MA | 2 |
| Leunissen, HD | 1 |
| van Opstal, JM | 2 |
| Wellens, HJ | 2 |
| Trohman, RG | 1 |
| Sahu, J | 1 |
| Tomcsányi, J | 1 |
| Merkely, B | 1 |
| Tenczer, J | 1 |
| Papp, L | 1 |
| Karlócai, K | 1 |
| Segura, I | 1 |
| García-Bolao, I | 1 |
| Merot, J | 1 |
| Charpentier, F | 1 |
| Poirier, JM | 1 |
| Coutris, G | 1 |
| Weissenburger, J | 1 |
| Glatter, K | 1 |
| Yang, Y | 1 |
| Chatterjee, K | 1 |
| Modin, G | 1 |
| Cheng, J | 1 |
| Kayser, S | 1 |
| Scheinman, MM | 1 |
| Yamada, S | 1 |
| Kuga, K | 1 |
| Yamaguchi, I | 1 |
| Silvetti, MS | 1 |
| Drago, F | 1 |
| Bevilacqua, M | 1 |
| Ragonese, P | 1 |
| Schoenmakers, M | 1 |
| de Groot, SH | 1 |
| Leunissen, JD | 1 |
| van Der Hulst, FF | 1 |
| Molenschot, MM | 1 |
| Pagano, L | 1 |
| Della Monica, R | 1 |
| Malinconico, M | 1 |
| Farkas, A | 1 |
| Leprán, I | 1 |
| Papp, JG | 1 |
| Arstall, MA | 1 |
| Hii, JT | 2 |
| Lehman, RG | 1 |
| Horowitz, JD | 1 |
| Wyse, DG | 1 |
| Gillis, AM | 1 |
| Duff, HJ | 1 |
| Solylo, MA | 1 |
| Mitchell, LB | 1 |
| Bajaj, BP | 1 |
| Baig, MW | 1 |
| Perrins, EJ | 1 |
| Morgan, JM | 1 |
| Lopes, A | 1 |
| Rowland, E | 1 |
| Quieffin, J | 1 |
| Brochet, E | 1 |
| Gamerman, G | 1 |
| Assayag, P | 1 |
| Antony, I | 1 |
| Valère, PE | 1 |
| Jorens, PG | 1 |
| Van den Heuvel, PA | 1 |
| Parizel, GA | 1 |
| Andrivet, P | 1 |
| Beaslay, V | 1 |
| Canh, VD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for amiodarone and Torsade de Pointes
| Article | Year |
|---|---|
QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Defibrillators, Implantable; Drug Inter | 2017 |
[Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Conduction System; Humans; In | 2003 |
Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Conduction System; Humans; Hy | 2003 |
A benefit-risk assessment of class III antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modalit | 2004 |
Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions.
Topics: Aged; Amiodarone; Drug Interactions; Female; Humans; Male; Retrospective Studies; Torsades de Pointe | 2005 |
Short QT syndrome: a case report and review of literature.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; ERG1 Pota | 2006 |
Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Electro | 2007 |
Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.
Topics: Amiodarone; Atrial Fibrillation; Humans; Tachycardia, Ventricular; Torsades de Pointes | 1994 |
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramid | 1993 |
What have clinical trials taught us about proarrhythmia?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiogra | 1996 |
Is there a need for new antiarrhythmic drugs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Propafeno | 1996 |
Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; | 1997 |
Drug-induced cardiac arrhythmias: incidence, prevention and management.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-Infective Agents; | 1997 |
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Myocardia | 1997 |
The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Conduction System; Heart Failur | 1997 |
1 trial available for amiodarone and Torsade de Pointes
| Article | Year |
|---|---|
Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Amiodarone; Anti-Arrhythmia Agents; Blood Pressure; Electrocardiograp | 2009 |
87 other studies available for amiodarone and Torsade de Pointes
| Article | Year |
|---|---|
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; | 2011 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Something Old, Something New: Reinventing Antiarrhythmic Drug Loading With Intravenous Sotalol.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Sotalol; Torsades de Pointes | 2023 |
New Onset Recurrent Syncope Triggered by Fever.
Topics: Amiodarone; Coronary Angiography; Drug Therapy, Combination; Electric Countershock; Electrocardiogra | 2020 |
Torsade de pointes in initiating hemodialysis: a case report.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Long QT Syndrome; Renal Dialysis; Torsades | 2020 |
TORSADES DE POINTES IN ELDERLY PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION TREATED BY SHORT-TERM PARENTERAL AMIODARONE THERAPY.
Topics: Acute Disease; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Ele | 2019 |
Torsade de pointes induced by intravenous amiodarone therapy accompanied by marked augmentation of the transmural dispersion of repolarization in a patient with tachycardia-induced-cardiomyopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Electrocardiography; Humans; Male; Torsa | 2021 |
Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Electrocardiography | 2021 |
Naturally occurring torsades de pointes and QT interval prolongation in a domestic cat.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cat Diseases; Cats; Electrocardiography; Long QT Syndro | 2021 |
Serious QT interval prolongation with ranolazine and amiodarone.
Topics: Acetanilides; Aged; Amiodarone; Electrocardiography; Female; Humans; Long QT Syndrome; Piperazines; | 2014 |
Torsade de pointes induced by amiodarone in a patient with heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Middle Aged; Torsades de Pointes | 2014 |
Intermittent QT prolongation induced by short-term oral amiodarone therapy.
Topics: Administration, Oral; Adult; Amiodarone; Anti-Arrhythmia Agents; Brugada Syndrome; Cardiac Conductio | 2014 |
Cardiac arrest and electrical storm due to recurrent torsades de pointes caused by concomitant clarithromycin, cotrimoxazole and amiodarone treatment.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clarithromycin; Drug Therapy, Combination; Electrocardiography; | 2014 |
[Paroxysmal atrial fibrillation well controlled. Why the sudden patient syncope?].
Topics: Amiodarone; Atrial Fibrillation; Clopidogrel; Coronary Disease; Diagnosis, Differential; Drug Therap | 2015 |
Torsade de pointes tachycardia in a patient on dronedarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Female; Humans; Torsades de Pointes | 2015 |
Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Hospitalizati | 2016 |
Anti-atrial Fibrillatory Versus Proarrhythmic Potentials of Amiodarone: A New Protocol for Safety Evaluation In Vivo.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; | 2017 |
A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia.
Topics: Adenine; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Cardiotonic Agents; Electric Cou | 2017 |
Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrioventricular Block; Bepridil; Dogs; Electrocardiogr | 2008 |
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Anti-Bacterial Agents; Antidepressive Agents; A | 2009 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
Multifactorial QT interval prolongation.
Topics: Alcoholism; Amiodarone; Antipsychotic Agents; Arrhythmias, Cardiac; Biomarkers; Citalopram; Cyclohex | 2010 |
A toxic combination.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Drug Therapy, Combination; Electroc | 2010 |
A dangerous fruit juice.
Topics: Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Beverages; Citrus paradisi; Electric Countersho | 2012 |
Pregnancy and short-coupled torsades de pointes.
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Female; | 2013 |
[Unexpected complication following esophageal variceal hemorrhage - Case 2/2011].
Topics: Amiodarone; Anti-Bacterial Agents; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inh | 2011 |
Torsade de pointes induced by citalopram and amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Depressive D | 2011 |
A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Female; He | 2011 |
Acquired long QT interval: a case series of multifactorial QT prolongation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Long QT Syndrome; Male; Middle Aged | 2011 |
Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Electrocardiography; El | 2012 |
Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Heart; Heart | 2012 |
Did you know? Why amiodarone requires diligent monitoring?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Interactions; Drug Monitoring; Female; Humans; Long Q | 2011 |
In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carbazoles; Carv | 2012 |
Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Ag | 2012 |
Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting.
Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; D | 2012 |
Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Dogs; Dose-Respo | 2002 |
Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.
Topics: Aged; Amiodarone; Anti-Allergic Agents; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; | 2003 |
Amiodarone-associated "torsade de pointes". Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease.
Topics: Acetyldigoxins; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2003 |
Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Bradycardia; Electrocardiography | 2004 |
[Amiodarone-induced torsade de pointes--five case reports].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Conduction System; Huma | 2004 |
[Torsade de pointes secondary to amiodarone overdose].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Torsades de Pointes | 2004 |
Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Disease Models, Animal; Drug Administr | 2004 |
The degree of potassium channel blockade and the risk of torsade de pointes: the truth, nothing but the truth, but not the whole truth.
Topics: Acetanilides; Amiodarone; Anti-Arrhythmia Agents; Humans; Piperazines; Potassium Channel Blockers; R | 2005 |
QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Drug Interacti | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Sex Factors; Sotalol; | 2005 |
QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Interactions; Electric Countershock; Female; Heart Co | 2006 |
Letter from Konstantinos P. Letsas et al. - invited editorial comment.
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Interactions; Humans; Hypnotics and Sedatives; Long QT Synd | 2006 |
"Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Arter | 2006 |
Use of a failing rabbit heart as a model to predict torsadogenicity.
Topics: Amiodarone; Animals; Cardiac Output, Low; Cisapride; Dose-Response Relationship, Drug; Electrocardio | 2006 |
Late presentation of a cardiomyopathy provoked by sudden emotional stress.
Topics: Acute Disease; Adult; Amiodarone; Cardiomyopathies; Contraindications; Female; Humans; Stress, Psych | 2006 |
Clinical study of amiodarone-associated torsade de pointes in Chinese people.
Topics: Amiodarone; Anti-Arrhythmia Agents; China; Female; Humans; Male; Risk Factors; Torsades de Pointes | 2006 |
Torsade de pointes induced by short-term oral amiodarone therapy.
Topics: Administration, Oral; Adult; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillat | 2006 |
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; DNA Mutational Analysis; Electrocardiog | 2007 |
[Long QT syndrome induced by cordaron and quinidine].
Topics: Amiodarone; Anemia, Hemolytic; Anti-Arrhythmia Agents; Female; Humans; Hypertension; Long QT Syndrom | 2007 |
Amiodarone--avoid the danger of torsade de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Female; Humans; Tachyca | 2008 |
Amiodarone-associated macroscopic T-wave alternans and torsade de pointes unmasking the inherited long QT syndrome.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Electrocardiography; Humans; L | 2008 |
Dolasetron-induced torsades de pointes.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Antiemetics; Cardiopulmonary Resusc | 2007 |
"Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hepatic Encephalopathy; Human | 2009 |
Amiodarone and torsades de pointes in patients with advanced heart failure.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square Distribution; Deat | 1995 |
[Torsade de pointes during anti-arrhythmia treatment with amiodarone].
Topics: Amiodarone; Cardiac Complexes, Premature; Electrocardiography; Humans; Male; Middle Aged; Torsades d | 1993 |
[Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects].
Topics: Aged; Amiodarone; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Long QT Syndro | 1994 |
Amiodarone and torsade de pointes.
Topics: Amiodarone; Coronary Disease; Humans; Risk Factors; Torsades de Pointes | 1995 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
['Cardiac ballet' with and without amiodarone].
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography; Female; Humans; | 1993 |
[Torsade de pointes during quinidine and amiodarone therapy].
Topics: Amiodarone; Catheter Ablation; Female; Humans; Middle Aged; Pacemaker, Artificial; Quinidine; Torsad | 1996 |
Torsade de pointes occurring early during oral amiodarone treatment.
Topics: Amiodarone; Anti-Arrhythmia Agents; Causality; Electrocardiography; Female; Humans; Middle Aged; Tor | 1996 |
More on amiodarone and torsade de pointes.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Torsades de Pointes | 1996 |
Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Electrocardiography, Ambulatory; Fem | 1997 |
Amiodarone-induced adverse effects at the beginning of oral therapy: clinical implications.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Humans; Lung; Torsades de Pointes | 1998 |
Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias.
Topics: Action Potentials; Administration, Oral; Amiodarone; Anesthesia; Animals; Anti-Arrhythmia Agents; Do | 1999 |
Drug-induced torsade de pointes.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Heart Arrest; Humans; Male; Procainam | 1999 |
Early proarrhythmia during intravenous amiodarone treatment.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart F | 1999 |
Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
Topics: Aged; Amiodarone; Antiprotozoal Agents; Electrocardiography; Follow-Up Studies; Humans; Leishmaniasi | 1999 |
Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
Topics: Action Potentials; Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Cardiac Pacing | 1999 |
Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Therapy, Combina | 2001 |
Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Electrocard | 2001 |
Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Child; Dose-Respo | 2001 |
Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
Topics: Action Potentials; Administration, Oral; Amiodarone; Anesthesia; Animals; Anti-Arrhythmia Agents; Ar | 2001 |
[Proarrhythmia caused by amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Torsades de Pointes | 2001 |
Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Amiodarone; Animals; Anti-Arrhythmi | 2002 |
Sotalol-induced torsade de pointes: management with magnesium infusion.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; Electrocardiography, Ambula | 1992 |
Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Conduction System; Huma | 1992 |
Amiodarone-induced torsades de pointes: the possible facilitatory role of digoxin.
Topics: Administration, Oral; Aged; Amiodarone; Digoxin; Drug Interactions; Electrocardiography; Female; Hum | 1991 |
Sudden cardiac death while taking amiodarone therapy: the role of abnormal repolarization.
Topics: Adult; Amiodarone; Electrocardiography; Electrophysiology; Heart Arrest; Humans; Long QT Syndrome; M | 1991 |
[Ventricular arrhythmia following thioridazine poisoning].
Topics: Amiodarone; Female; Humans; Middle Aged; Tachycardia; Thioridazine; Torsades de Pointes; Ventricular | 1991 |
Amiodarone and torsades de pointes.
Topics: Amiodarone; Electrocardiography; Humans; Torsades de Pointes | 1990 |
Torsades de pointe with flecainide-amiodarone therapy.
Topics: Aged; Amiodarone; Electrocardiography; Female; Flecainide; Humans; Torsades de Pointes | 1990 |